Skip to main content

Advertisement

Table 1 Characteristics of 64 relapsed case subjects and 64 successfully treated matched control subjects with acute lymphoblastic leukemia selected from trials ALL-BFM 86 and ALL-BFM 90

From: Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy

  Cases (%) Controls (%)
Trial   
   ALL-BFM 86 35 (54.7) 35 (54.7)
   ALL-BFM 90 29 (45.3) 29 (45.3)
Sex   
   Male 42 (65.6) 42 (65.6)
   Female 22 (34.4) 22 (34.4)
Age (y)   
   <1 1 (1.6) 1 (1.6)
   1-9 56 (87.5) 56 (87.5)
   10-14 6 (9.4) 7 (10.9)
   15-18 1 (1.6) -
WBCa (103/μl)   
   <10 42 (65.6) 41 (64.1)
   10-<50 21 (32.8) 22 (34.4)
   ≥ 50 1 (1.6) 1 (1.6)
Immunophenotype   
   c-ALLb 54 (84.4) 54 (84.4)
   pre-B-ALLc 10 (15.6) 10 (15.6)
Risk groupd   
   standard 23 (35.9) 23 (35.9)
   intermediate 41 (64.1) 41 (64.1)
   high - -
DNA indexe   
   <1.16 30 (46.9) 30 (46.9)
   ≥ 1.16 12 (18.8) 7 (10.9)
   not examined 22 (34.4) 27 (42.2)
Genotype   
   normal 4 (6.3) 10 (15.6)
   11q23 abberations - 1 (1.6)
   t(1;19) 1 (1.6) -
   t(9;22) - -
   other 15 (23.3) 13 (20.3)
   not examined 44 (68.8) 40 (62.5)
  1. a white blood cell count b common acute lymphoblastic leukemia c precursor B-cell acute lymphoblastic leukemia d therapy stratification in risk groups was mainly based on initial leukemic cell mass estimate and initial treatment response [1618], e ratio of DNA content of leukemic G0/G1 cells to normal diploid lymphocytes